Skip to main content

Table 1 Parameter estimates from final population pharmacokinetic model of ivermectin in healthy volunteers

From: Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles

Parameter

Population estimates (%RSE)b

95% CIb

IIV [%CV] (%RSE)b

95% CIb

F

1 (fixed)

–

10.7 (42.9)

4.82–14.1

ka (h−1)

0.317 (3.97)

0.296–0.343

–

–

MTT (h)

0.496 (17.1)

0.350–0.679

56.1 (36.2)

31.9–77.4

CL/F (l/h)

9.02 (5.49)

8.08–10.1

23.1 (25.2)

15.3–27.5

VC/F (l)

115 (4.38)

106–125

–

–

Q/F (l/h)

16.2 (5.34)

14.7–18.1

–

–

VP/F (l)

157 (6.59)

139–178

22.8 (36.0)

13.5–29.9

σ

0.0361

0.0263–0.0463

–

–

Secondary parametersc

 Terminal half-life (h)

25.0 (23.7–29.5)

 AUC0–168 (ng × h/ml)

1331 (919–1406)

 Cmax (ng/ml)

45.7 (40.3–46.9)

 Tmax (h)

4.76 (4.67–5.04)

  1. F relative bioavailability, k a absorption rate constant, MTT mean transit absorption time, CL/F apparent oral elimination clearance, V C /F apparent volume of distribution of central compartment, Q/F apparent inter-compartmental clearance, V P /F apparent volume of distribution of peripheral compartment, σ variance of the residual variability
  2. aPopulation mean values and inter-individual variability (IIV) were estimated by NONMEM. The coefficient of variation (%CV) for IIV was calculated as \(100 \times \sqrt {e^{estimate} - 1}\)
  3. bThe relative standard error (%RSE) was calculated as \(100 \times \left( {\frac{\text{SD}}{{{\text{Mean}}\;{\text{value}}}}} \right)\) from the non-parametric bootstrap results (n = 1000). The 95% confidence interval (95% CI) is presented as the 2.5–97.5 percentiles of the bootstrap estimates
  4. cPost hoc parameter estimates from final pharmacokinetic model of ivermectin presented as median (interquartile range)
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us